Compare Cytokinetics Inc (CYTK) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Nutanix Inc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Nutanix Inc trades at $74.63 (market cap $19.78B). The key difference: Nutanix Inc is far larger — about 2.3× Cytokinetics Inc's market cap, and Nutanix Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Nutanix Inc for 17 Days on average.
| CYTK | NTNX | |
|---|---|---|
Market Cap | $8.62B | $19.78B |
Volume | 2,594,626 | 1,717,619 |
Sector | Health | Technology |
52-Week High | $87.26 | $74.63 |
52-Week Low | $54.76 | $34.41 |
Typical Hold Time | 19 Days | 17 Days |
Enterprise Value | $8.72B | $18.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% today, amid bearish technical signals but strong analyst optimism. The stock shows negative profitability with a -1,321.12% net income margin and P/S ratio of 114, reflecting high growth expectations. Recent Phase 3 trial successes for aficamten in hypertrophic cardiomyopathy position the company for potential FDA approval and commercial expansion, driving the 97% buy rating consensus with a $112.60 price target.
The outlook balances clinical progress against financial strain. While aficamten's recent data and commercial launch of MYQORZO offer significant upside, persistent cash burn and high valuation multiples present substantial risk. Investors face binary outcomes dependent on regulatory success and market penetration versus ongoing operational losses.
Nutanix (NTNX) trades at $73.08, down 0.46% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.60 beating expectations of $0.49, and impressive net income margin expansion to 52.81% in 2026. Recent Gartner Magic Quadrant recognitions highlight competitive strength in server virtualization and container management.
The outlook remains positive with analyst consensus targeting $76.11, though elevated valuation ratios and negative ROE present risks. Key catalysts include external storage growth and AI initiatives, while supply chain pressures and competitive threats warrant monitoring. The stock's proximity to resistance at $74 suggests potential near-term consolidation before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
